Morgan Stanley
KRSA

Morgan Stanley’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Morgan Stanley’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Hold
0
– -$2 – 8457
2026
Q1 		– Hold
0
– – – 8256
2025
Q4 		– Sell
-93
Closed -$166 – 8173
2025
Q3 		$1.49K Hold
93
– – ﹤0.01% 7352
2025
Q2 		$1.89K Hold
93
– – ﹤0.01% 7237
2025
Q1 		$1.62K Hold
93
– – ﹤0.01% 7214
2024
Q4 		$2.09K Hold
93
– – ﹤0.01% 7190
2024
Q3 		$1.68K Hold
93
– – ﹤0.01% 7163
2024
Q2 		$1.49K Hold
93
– – ﹤0.01% 7104
2024
Q1 		$2.08K Sell
93
-7
-7% -$22 ﹤0.01% 7060
2023
Q4 		$2.34K Sell
100
-18
-15% -$52 ﹤0.01% 7016
2023
Q3 		$2.82K Hold
118
– – ﹤0.01% 7051
2023
Q2 		$3.39K Buy
118
+32
+37% +$166 ﹤0.01% 7072
2023
Q1 		$5.22K Buy
86
+63
+274% +$795 ﹤0.01% 7038
2022
Q4 		$2.16K Sell
23
-1
-4% -$12 ﹤0.01% 7353
2022
Q3 		$3K Sell
24
-14
-37% -$241 ﹤0.01% 7374
2022
Q2 		$3K Sell
38
-242
-86% -$3.47K ﹤0.01% 7503
2022
Q1 		$43K Sell
280
-240
-46% -$5.78K ﹤0.01% 6779
2021
Q4 		$125K Sell
520
-12
-2% -$567 ﹤0.01% 6306
2021
Q3 		$229K Buy
532
+31
+6% +$2.03K ﹤0.01% 5926
2021
Q2 		$274K Buy
501
+231
+86% +$14.5K ﹤0.01% 5855
2021
Q1 		$105K Sell
270
-2,681
-91% -$201K ﹤0.01% 5977
2020
Q4 		$1.26M Buy
2,951
+2,506
+563% +$171K ﹤0.01% 4516
2020
Q3 		$379K Buy
445
+387
+667% +$44.3K ﹤0.01% 4777
2020
Q2 		$48K Buy
58
+38
+190% +$3.18K ﹤0.01% 5683
2020
Q1 		$7K Sell
20
-217
-92% -$15.5K ﹤0.01% 6102
2019
Q4 		$89K Buy
237
+166
+234% +$15.5K ﹤0.01% 5692
2019
Q3 		$121K Buy
71
+55
+344% +$11.9K ﹤0.01% 5368
2019
Q2 		$25K Buy
+16
New +$4.53K ﹤0.01% 5857

Other funds holding KRSA

KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Morgan Stanley's KRSA Position: Q2 2026 in Review

Morgan Stanley held its Korsana Biosciences, Inc. Common Stock (KRSA) position steady in Q2 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #8457.

Morgan Stanley first reported a position in KRSA in Q2 2019 and has held it in 26 quarters since. The position peaked at $1.26M in Q4 2020. 21 funds tracked by Wall St. Rank hold KRSA as of Q2 2026.

  • Morgan Stanley held 0 shares of Korsana Biosciences, Inc. Common Stock worth $0 as of Q2 2026.
  • Morgan Stanley left its Korsana Biosciences, Inc. Common Stock share count unchanged in Q2 2026.
  • Korsana Biosciences, Inc. Common Stock made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8457 holding.
  • Morgan Stanley first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and has held it in 26 quarters since.
  • Morgan Stanley's Korsana Biosciences, Inc. Common Stock position peaked at $1.26M in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.